The Medical Devices sector report, “Drug Eluting Stents (DES) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update' provides comprehensive information about the Drug Eluting Stents (DES) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Drug eluting stents (DES) release drugs locally and can be coated with a polymeric material. The stent releases an antiproliferative or immunosuppressive drug over time, leaving behind the metallic stent in the artery.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Drug eluting stents (DES) release drugs locally and can be coated with a polymeric material. The stent releases an antiproliferative or immunosuppressive drug over time, leaving behind the metallic stent in the artery.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Drug Eluting Stents (DES) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
2 Introduction
3 Products under Development
4 Drug Eluting Stents (DES) - Pipeline Products under Development by Companies
5 Drug Eluting Stents (DES) Companies and Product Overview
7 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Vascular Inc
- Adcomp Technologies Inc.
- Advanced Bifurcation Systems Inc
- Aeon Bioscience
- B. Braun Melsungen AG
- Biosensors International Group Ltd
- Biotronik AG
- Biotronik SE & Co KG
- Boston Scientific Corp
- Cardionovum GmbH
- Cardiorev Pte Ltd (Inactive)
- Columbia University
- Concept Medical Inc
- Cordis Corp
- DISA Vascular (Pty) Ltd
- Elixir Medical Corp
- Endomimetics LLC
- Envision Scientific Pvt Ltd
- I.B.S. S.p.A.
- InspireMD Inc
- JW Medical Systems Ltd
- Kaneka Corp
- MangoGen Pharma Inc
- Medinol Ltd
- Medlogics Device Corp (Inactive)
- Medtronic Plc
- MicroPort Scientific Corp
- MIV Therapeutics Inc
- Northwestern University
- NuVascular Technologies Inc
- Relisys Medical Devices Ltd
- REVA Medical Inc
- Shandong Rientech Medical Tech Co Ltd
- Shanghai BIOMAGIC Medical Device Co Ltd
- Shanghai MicroPort Medical Group Co Ltd
- Sino Medical Sciences Technology Inc
- Stentys SA
- Svelte Medical Systems Inc
- Terumo Corp
- Terumo Interventional Systems
- TissueGen Inc
- Translumina Therapeutics LLP
- University of Strathclyde
- VasoTech Inc.
